Prime Medicine (PRME) News Today $2.00 +0.05 (+2.56%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.94 -0.06 (-3.25%) As of 03/27/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.38March 26 at 2:57 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Price Target Raised to $16.00March 23, 2025 | americanbankingnews.comWedbush Estimates Prime Medicine FY2029 EarningsMarch 23, 2025 | americanbankingnews.comWedbush Forecasts Prime Medicine FY2029 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Wedbush issued their FY2029 earnings per share estimates for Prime Medicine in a report released on Tuesday, March 18th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($1.27) per share for the year. WedMarch 22, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Average Recommendation of "Buy" by AnalystsPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has received an average rating of "Buy" from the ten research firms that are presently covering the firm, MarketBeat.com reports. Nine analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the coMarch 22, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Expected to Rise, Chardan Capital Analyst SaysChardan Capital upped their target price on shares of Prime Medicine from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday.March 21, 2025 | marketbeat.comPrime Medicine price target raised to $16 from $15 at ChardanMarch 20, 2025 | markets.businessinsider.comWhy Prime Medicine Stock Was Climbing Higher This WeekMarch 20, 2025 | fool.comPrime Medicine's (PRME) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Prime Medicine in a research note on Wednesday.March 20, 2025 | marketbeat.comPrime Medicine Advances AATD Program With Prime Editing For Potential Curative TreatmentMarch 20, 2025 | nasdaq.comWedbush Reaffirms "Outperform" Rating for Prime Medicine (NYSE:PRME)March 20, 2025 | americanbankingnews.comPrime Medicine's (PRME) "Outperform" Rating Reiterated at WedbushWedbush restated an "outperform" rating and issued a $13.00 target price (up from $12.00) on shares of Prime Medicine in a research note on Tuesday.March 19, 2025 | marketbeat.comWhy Prime Medicine Stock Is Soaring TodayMarch 19, 2025 | fool.comPrime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth PotentialMarch 19, 2025 | tipranks.comPrime Medicine unveils program for treatment of AATDMarch 18, 2025 | markets.businessinsider.comPrime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy RatingMarch 18, 2025 | tipranks.comPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)March 18, 2025 | globenewswire.comPrime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy RatingMarch 18, 2025 | tipranks.comChardan Capital Estimates Prime Medicine FY2025 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Prime Medicine in a research report issued to clients and investors on Monday, March 10th. Chardan Capital analyst G. Livshits expects that the company will post earnings peMarch 14, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Releases Quarterly Earnings ResultsPrime Medicine (NYSE:PRME - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($1.65) earnings per share for the quarter.March 8, 2025 | marketbeat.comQ1 EPS Estimates for Prime Medicine Lifted by HC WainwrightPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Prime Medicine in a research note issued on Monday, March 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($March 7, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)March 4, 2025 | markets.businessinsider.comPrime Medicine (NYSE:PRME) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Prime Medicine in a research report on Monday.March 3, 2025 | marketbeat.comChardan Capital Reiterates Buy Rating for Prime Medicine (NYSE:PRME)Chardan Capital reiterated a "buy" rating and set a $15.00 price target on shares of Prime Medicine in a research report on Monday.March 3, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Receives "Outperform" Rating from WedbushWedbush restated an "outperform" rating and issued a $12.00 price target on shares of Prime Medicine in a research report on Friday.March 1, 2025 | marketbeat.comPrime Medicine Reports 2024 Financial Results and ProgressFebruary 28, 2025 | tipranks.comPrime Medicine, Inc.: Prime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesFebruary 28, 2025 | finanznachrichten.dePrime Medicine reports FY24 EPS ($1.65) vs ($2.18) last yearFebruary 28, 2025 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)February 28, 2025 | markets.businessinsider.comPrime Medicine Reports Full Year 2024 Financial Results and Provides Business UpdatesFebruary 28, 2025 | globenewswire.comARK Investment Management LLC Has $15.04 Million Holdings in Prime Medicine, Inc. (NYSE:PRME)ARK Investment Management LLC cut its holdings in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 9.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,150,233 shares of the company's stock after selling 510,486 shaFebruary 26, 2025 | marketbeat.comPrime Medicine to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by BrokeragesShares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) have received an average recommendation of "Buy" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating and one has given a strFebruary 24, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 100,275 Shares of Prime Medicine, Inc. (NYSE:PRME)Sumitomo Mitsui Trust Group Inc. lessened its position in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,090,180 shares of the company's stocFebruary 13, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Raised to Sell at StockNews.comStockNews.com raised shares of Prime Medicine to a "sell" rating in a research report on Tuesday.February 11, 2025 | marketbeat.comPrime Medicine: Gene Editing Company, Risky InvestmentFebruary 5, 2025 | seekingalpha.comKuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law FirmJanuary 30, 2025 | prnewswire.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Buy" by BrokeragesPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has received an average recommendation of "Buy" from the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation and one has assigned a strJanuary 30, 2025 | marketbeat.comPrime Medicine’s Promising Prospects and Potential Catalysts Justify Buy RatingJanuary 16, 2025 | markets.businessinsider.comStockNews.com Upgrades Prime Medicine (NYSE:PRME) to "Sell"StockNews.com upgraded Prime Medicine to a "sell" rating in a report on Wednesday.January 15, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Upgraded at StockNews.comStockNews.com raised shares of Prime Medicine to a "sell" rating in a report on Monday.January 6, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Buy" from AnalystsPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of "Buy" from the eleven ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, nine have given a buy recommendaJanuary 5, 2025 | marketbeat.comKuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law FirmJanuary 4, 2025 | markets.businessinsider.comIs Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?December 31, 2024 | insidermonkey.comWhy Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comPrime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comPrime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comPrime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.comStockNews.com upgraded Prime Medicine to a "sell" rating in a report on Tuesday.December 24, 2024 | marketbeat.comJMP Securities Initiates Coverage of Prime Medicine (PRME) with Market Outperform RecommendationDecember 11, 2024 | msn.comPrime Medicine (NYSE:PRME) Raised to Strong-Buy at Citizens JmpCitizens Jmp raised Prime Medicine to a "strong-buy" rating in a research report on Tuesday.December 11, 2024 | marketbeat.com Remove Ads Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.720.78▲Average Medical News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼93▲PRME Articles Average Week Remove Ads Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mineralys Therapeutics News Nurix Therapeutics News Vir Biotechnology News Intellia Therapeutics News Collegium Pharmaceutical News Arcus Biosciences News Rocket Pharmaceuticals News Xencor News Zymeworks News Xeris Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
